Ascendiant Capital Markets Issues Pessimistic Forecast for Lucid Diagnostics (NASDAQ:LUCD) Stock Price

Lucid Diagnostics (NASDAQ:LUCD) had its target price cut by research analysts at Ascendiant Capital Markets from $7.25 to $7.00 in a research report issued on Monday,Benzinga reports. The brokerage presently has a “buy” rating on the stock.

LUCD has been the topic of a number of other reports. Cantor Fitzgerald reduced their price objective on shares of Lucid Diagnostics from $3.00 to $2.00 and set an “overweight” rating on the stock in a research note on Friday, November 15th. Canaccord Genuity Group upgraded Lucid Diagnostics to a “strong-buy” rating in a research report on Tuesday, August 13th. Needham & Company LLC restated a “buy” rating and set a $2.50 price target on shares of Lucid Diagnostics in a report on Thursday, November 14th. Finally, Canaccord Genuity Group reiterated a “buy” rating and issued a $3.00 price objective on shares of Lucid Diagnostics in a report on Thursday, November 14th. Four analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat.com, the company has an average rating of “Buy” and a consensus target price of $3.63.

Lucid Diagnostics Trading Down 3.1 %

NASDAQ LUCD opened at $0.79 on Monday. The company has a 50 day moving average of $0.91 and a 200-day moving average of $0.85. The company has a market cap of $46.80 million, a price-to-earnings ratio of -0.69 and a beta of 1.42. Lucid Diagnostics has a 1-year low of $0.63 and a 1-year high of $1.58.

Lucid Diagnostics Company Profile

Lucid Diagnostics Inc operates as a commercial-stage medical diagnostics technology company in the United States. The company focuses on patients with gastroesophageal reflux disease (GERD) who are at risk of developing esophageal precancer and cancer, primarily highly lethal esophageal adenocarcinoma.